Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading
GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

GSK announced today it has begun shipping FLUARIX QUADRIVALENT (Influenza Vaccine) doses to U.S. healthcare providers. This is the first shipment of GSK’s U.S. flu vaccine supply for the flu season, following licensing and lot-release approval from the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research. [More]
Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Firstly, paracetamol has been the first-line recommended treatment for osteoarthritis pain for very many years and, secondly, it is readily available over the counter and can be bought in relatively large quantities. [More]
First step in developing evidence-based concussion guidelines

First step in developing evidence-based concussion guidelines

A research review identifying the clinical indicators most strongly associated with concussion is an important first step in the process of developing evidence-based guidelines for concussion diagnosis, prognosis, and treatment, according to a new report published by Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]
Prisons cut health care costs, but aging inmate population threatens budgets

Prisons cut health care costs, but aging inmate population threatens budgets

Health care for prisoners has long taken a bite out of state budgets, but a new report from the Pew Charitable Trusts says prisons have cut back on those costs. They've outsourced some health services, used tele-medicine, and simply incarcerated fewer people. But the aging of the inmate population threatens to drive those costs right back up (Gorenstein, 7/9). [More]
Trial to evaluate safety of FRED- flow diversion system for treatment of aneurysms

Trial to evaluate safety of FRED- flow diversion system for treatment of aneurysms

After Susan Wakulich was told she had an aneurysm, she figured an invasive brain surgery and lengthy recovery lay ahead of her. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. [More]
Pain control in osteoarthritis patients: an interview with Dr. Clarence Young, Chief Medical Officer and John Vavricka, President and CEO, Iroko Pharmaceuticals

Pain control in osteoarthritis patients: an interview with Dr. Clarence Young, Chief Medical Officer and John Vavricka, President and CEO, Iroko Pharmaceuticals

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients. [More]
FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

Protein Sciences Corporation announced today that the FDA has approved the Company's strain change amendment for its seasonal influenza vaccine, Flublok. [More]
Perrigo receives final approval from FDA for congestion relief tablets

Perrigo receives final approval from FDA for congestion relief tablets

Perrigo Company today announced that it was the first to receive final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ibuprofen and phenylephrine hydrochloride tablets, 200 mg/10 mg (over-the-counter), the store brand equivalent to Advil Congestion Relief Tablets, 200 mg/10 mg. [More]
State highlights: Calif. rejecting 'free money'; N.C. Medicaid changes, problems; Ill. readies employer contraception coverage vote

State highlights: Calif. rejecting 'free money'; N.C. Medicaid changes, problems; Ill. readies employer contraception coverage vote

Consumer advocates and some legislators were surprised and frustrated when California health officials recently refused a $6 million donation to help people re-up their Medi-Cal health coverage. Now two senators have proposed an unusual solution: a bill to force the state to accept the offer from The California Endowment (Gorman, 7/4). [More]
Headbanging to Motörhead thought to have caused bleeding in the brain

Headbanging to Motörhead thought to have caused bleeding in the brain

A recent report in the Lancet describes the case of a man who developed bleeding in the brain after headbanging at a Motörhead concert. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Therapeutics, LLC, today announced that the Company has entered into a transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for AcipHex® Sprinkle™ (rabeprazole sodium), Delayed-Release Capsules, 5 mg and 10 mg, for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks. [More]
Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years. [More]
ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. [More]
Researchers identify two classes of anti-depressants that reduce symptoms of depression

Researchers identify two classes of anti-depressants that reduce symptoms of depression

Depression is common in cancer, up to half of all patients facing the disease experience depressive symptoms, ranging from mild to severe. When depression co-exists with cancer, patients may be at an increased risk of death from cancer and from suicide. [More]
Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. [More]
Researchers perform systematic review to identify best treatments for cancer-related depression

Researchers perform systematic review to identify best treatments for cancer-related depression

Depression is common in cancer, up to half of all patients facing the disease experience depressive symptoms, ranging from mild to severe. When depression co-exists with cancer, patients may be at an increased risk of death from cancer and from suicide. [More]
Tips to protect children from summer bugs

Tips to protect children from summer bugs

Mike Gittelman, MD, Co-Director, Comprehensive Children's Injury Center and the experts at Cincinnati Children's Hospital Medical Center want to make sure that families and children stay safe while playing outdoors this summer. [More]
Chronic migraine significantly impacts family relationships and activities

Chronic migraine significantly impacts family relationships and activities

A web-based study of 994 men and women with chronic migraine found that the condition significantly impacts family relationships and activities, including cancelled vacation plans and reduced quality time with partners and children. [More]